Sun Pharmaceuticals rating – Buy- One-offs hit bottomline in Q4FY22
时间:2024-06-26 13:18:57 阅读(143)
Sun reported net loss of Rs 22.8 bn in Q4, mainly on one-offs of Rs 39.4 bn (Rs 37.2 bn of provisions related to settlement of antitrust litigation for valganciclovir, valsartan and esomeprazole, Rs 1.6 bn of provisions for settlement with various purchaser groups and Rs 563.5 m for restructuring of certain businesses). It also booked a one-off tax gain of Rs 764.2 m and FX gain of Rs 1.6 bn. Adjusting for one-offs and FX, PAT was Rs 14.2 bn (~19% below HSBCe). EBITDA margins at 23.1% fell 109bps y-o-y and 346bps q-o-q on input cost pressure and normalisation of expenses.
Traction continues for specialty sales: Global sales for the specialty products portfolio of $185 m grew ~33% y-o-y (+1% q-o-q) on strong traction in key brands Ilumya, Cequa, and Odomzo. Specialty sales in FY22 grew 42% to $673 m (13% of total revenues vs 7% in FY18). Global sales for Ilumya (incl. milestones and royalties) reached $315 m (+81% y-o-y). Winlevi (novel acne drug launched in Nov 2021) is seeing good traction and around 9K prescribing doctors (out of 15K) have prescribed it. We expect sales traction to continue for key brands on improving patient footfall (elective procedures are not yet back to pre-COVID-19 levels), better commercial execution and increasing market size.
A scientist works in a lab owned by Sun Pharmaceuticals Industries Ltd in Mumbai, India, on Tuesday, May 22, 2007. Sun Pharmaceutical Industries Ltd., India’s biggest drugmaker, agreed to buy Taro Pharmaceutical Industries Ltd., an unprofitable producer of generic medicines, giving it factories and distribution assets in the U.S. Photographer: Abhijit Bhatlekar/Bloomberg NewsRetain Buy rating: We remain positive on Sun’s efforts in the specialty products portfolio, which we believe will likely achieve Ebitda breakeven over the next 2-3 years, resulting in significant operating leverage. We assume specialty sales to be key driver of US sales, with sales CAGR of 17.2% for FY22-25e, while we assume base generic and Taro sales stabilising at current levels.
Sun plans to expand India sales headcount by 10% in FY23e to improve market coverage and de-clutter some marketing divisions. We assume its India segment sustaining above-market growth on new launches and better reach. The outlook remains largely steady for other segments (RoW, emerging markets, API, etc.) barring any short-term fluctuations. Post Q4, we adjust our estimates per current visibility leading to 3.3%/3.5% cuts in EPS for FY23/24e. Our TP is Rs 1,040 (from Rs 1,075).
上一篇:India Mourns the Loss of Brigadier AJS Behl- A Tribute to a Gallant Soldier
下一篇:Year-ahead in space expedition- Pivotal space missions set stage for cosmos exploration in 2024
猜你喜欢
- Indian bond yields may start week tad higher tracking US peers
- Arvind Kejriwal to undertake three-day Gujarat visit as AAP airs arrest fears
- Nifty needs to hold above 17350 for further upside, support shifts higher to 17250
- India-focused portfolio outperforms benchmarks- GREED & fear
- India bond yields crash after RBI surprises with status quo on rates
- Agricultural, Fertilizer stocks jump as FM Sitharaman announces Agricultural Accelerator in Budget 2023
- IIFL Securities says 80 companies have lined up initial public offerings
- Indian bond yields to edge higher, heavy state debt supply hurts
- Nifty short-term trend negative, pullback rally to see resistance at 18150; sell these stocks to avoid losses